Clinical Trial Update: An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects

View source ↗

Summary

The document describes an open-label, single-dose pharmacokinetic study of a 14 mg granisetron transdermal patch conducted in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• granisetron patch (granisetron)

Snippet

Sponsor: Taipei Medical University WanFang Hospital | Conditions: Cancer, Vomiting | Status: UNKNOWN